(Q46121548)

English

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

scientific article published on 13 February 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy (English)

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

P Hadji

1

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

M Ziller

2

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

D G Kieback

3

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

W Dornoff

4

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

H W Tessen

5

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

T Menschik

6

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

J Kuck

7

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

F Melchert

8

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

A Hasenburg

9

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

publication date

13 February 2009

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

Annals of Oncology

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

20

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

7

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

1203-1209

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Bone loss and fracture risk associated with cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

The causes and treatment of bone loss associated with carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Practical guidance for the management of aromatase inhibitor-associated bone loss

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN762

21 January 2018

Identifiers

10.1093/ANNONC/MDN762

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19218306

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46121548&oldid=2093435542"